Adverse effect · Semaglutide

How common is lean mass loss with Semaglutide?

B
Grade B — probable, not settledSub-studies · effect size: moderate · adverse
Short answerProbable, not settled. Human data exist (Sub-studies) and mostly agree, showing a moderate effect — but too few, too small, or not yet peer-reviewed for a firm answer. A share of weight lost is lean tissue; magnitude and clinical importance still debated.

What the studies show

A share of weight lost is lean tissue; magnitude and clinical importance still debated.

Human trials exist and mostly agree, but there are too few of them, they are too small, or one big one is still reading out. Expect the grade to move.

  1. 1
    Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1).N Engl J Med, 2021;384:989–10021,961 adults; −14.9% vs −2.4% at 68 weeks.
  2. 2
    Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension.Diabetes Obes Metab, 2022Two-thirds of lost weight regained within a year of stopping.

In context

Semaglutide is a once-weekly GLP-1 receptor agonist approved for type 2 diabetes and, at a higher dose, for weight management. In large randomised trials it produces roughly 15% average weight loss over 68 weeks and reduces major cardiovascular events in people with existing heart disease. Gastrointestinal side effects are common and are the main reason people stop. It is a prescription medicine; products sold outside that channel are unlicensed copies.

Semaglutide is approved (rx). Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Semaglutide proven to cause lean mass loss?
Not yet settled. Sub-studies — LYO grades it B, meaning probable but liable to change as trials read out.
What studies are behind the grade?
A share of weight lost is lean tissue; magnitude and clinical importance still debated.
Is Semaglutide approved for this?
Semaglutide is an approved medicine (Approved (Rx)); whether this particular outcome is a licensed indication is stated on the compound page's regulation section.

Other outcomes for Semaglutide

Reviewed 1 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →